About the Company
We do not have any company description for FATE THERAPEUTICS INC at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on FATE THERAPEUTICS INC
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have ...
It's been a good week for Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders, because the company has just released its latest yearly results, and the shares gained 4.5% to US$7.14. The results ...
Fate Therapeutics Announces Retirement of Chief Scientific Officer ...
Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. About Fate Therapeutics, Inc.
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Fate Therapeutics Inc. faces a ...
Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $4 ...
Wells Fargo & Company dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th.
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial ...
On April 2, 2020, Fate Therapeutics announced a collaboration agreement with Janssen Biotech, Inc. (the “Janssen Collaboration Agreement”), under which Fate Therapeutics received a $50 million ...
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data
Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc.
Fate Therapeutics (NASDAQ:FATE) Share Price Crosses Below Two Hundred ...
Posted by MarketBeat News on Apr 4th, 2025 Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Thursday .
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for ...
Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy, at the ...
As Fate Therapeutics, Inc.'s (NASDAQ:FATE)) market cap dropped by US ...
Insiders seem to have made the most of their holdings by selling US$4.2m worth of Fate Therapeutics, Inc. (NASDAQ:FATE) stock at an average sell price of US$43.64 during the past year. After the ...
Fate Therapeutics Inc Shares Close the Day 10.4% Higher - Nasdaq
Fate Therapeutics Inc (FATE) shares closed today 10.4% higher than it did at the end of yesterday. The stock is currently down 62.4% year-to-date, down 69.8% over the past 12 months, and up 568.7% ...
Shareholder Alert: Robbins LLP Informs Investors of Class Action ...
Contacts Aaron Dumas Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com ...
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts ...
Last week, you might have seen that Fate Therapeutics, Inc. (NASDAQ:FATE) released its full-year result to the market. The early response was not positive, with shares down 9.8% to US$1.01 in the ...
Similar Companies
Loading the latest forecasts...